Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (864.12.003, 016.156.415)
SBC was funded by the Wellcome Trust and the Autism Research Trust during the period of this work.
DM was supported by the NIHR Maudsley Biomedical Research Centre.
Received: 8 June 2020
Revised: 29 September 2020
Accepted: 19 October 2020
First Online: 6 November 2020
Conflict of interest
: J.K.B. has been a consultant to, advisory board member of, and a speaker for Janssen Cilag BV, Eli Lilly, Shire, Lundbeck, Roche, and Servier. He is not an employee of any of these companies and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, or royalties. CFB is director and shareholder in SBGNeuro Ltd. T.B. served in an advisory or consultancy role for Actelion, Hexal Pharma, Lilly, Lundbeck, Medice, Novartis, and Shire. He received conference support or speaker’s fee from Lilly, Medice, Novartis, and Shire. He has been involved in clinical trials conducted by the Shire and Vifor Pharma. He received royalities from Hogrefe, Kohlhammer, CIP Medien, and Oxford University Press. The present work is unrelated to the above grants and relationships. COIs. DM has served on advisory boards for Roche and Servier. The other authors report no biomedical financial interests or potential conflicts of interest.